Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590940 | 0.87 | TRPV1 (0.63) | TRPV1KDM4EALDH1A1HSP90AA1GAA | |
| SCHEMBL4591175 | 0.83 | TRPV1 (0.77) | TRPV1RAB9A | |
| SCHEMBL4591016 | 0.82 | TRPV1 (0.70) | TRPV1RAB9ANPSR1 | |
| SCHEMBL15779636 | 0.82 | TRPV1 (0.78) | TRPV1RAB9A | |
| SCHEMBL14083454 | 0.82 | TRPV1 (0.61) | TRPV1KDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL5934454 | 0.79 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL3873424 | 0.78 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL10324366 | 0.78 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL4590059 | 0.77 | TRPV1 (0.67) | TRPV1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL14083433 | 0.77 | TRPV1 (0.74) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664041-B1 | PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-07-02 | — | — | EP | claimed |
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885KDM4E 2121/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.